Cassava Sciences President and CEO Remi Barbier is hitting back at The New York Times, calling out the venerable newspaper for an alleged one-sided article that he claims misrepresented the research of his company by only using sources who were critical of Cassava.

U.S. Medicare limits coverage for Biogen’s Alzheimer’s drug Published April 7, 2022; 7:40 PM EDT By Deena Beasley April 7 (Reuters) – The U.S. government health plan for people age 65 and over on Thursday issued its final coverage policy for Biogen Inc’s (BIIB.O) Alzheimer’s drug, Aduhelm, moving forward with an unusually strict plan limiting […]

Billionaire Bill Gates and Estée Lauder Cos chairman emeritus Leonard Lauder said they will award $30 million over three years to encourage development of new tests for early detection of Alzheimer’s disease.